Legal Representation
Attorney
Douglas T. Johnson
USPTO Deadlines
Next Deadline
1749 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-05-07)
Due Date
May 07, 2030
Grace Period Ends
November 07, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 23, 2024 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Oct 31, 2024 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Oct 31, 2024 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Aug 7, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| May 7, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 7, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 1, 2024 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Mar 13, 2024 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Mar 13, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 4, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 26, 2024 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Feb 20, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 7, 2024 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Feb 7, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jan 31, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 2, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Jan 2, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Dec 18, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 12, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 12, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 12, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 12, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 8, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 7, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 7, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 22, 2023 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jun 27, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jun 27, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| May 20, 2023 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| May 19, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 18, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 11, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Oct 18, 2022 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Oct 14, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 13, 2022 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
Class 042
Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
Class 044
Medical treatment by gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics
Classification
International Classes
005
042
044